Eagle Genomics

About:

Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data.

Website: http://www.eaglegenomics.com

Twitter/X: eaglegen

Top Investors: Future Planet Capital, Innovate UK, Abrdn, ETF Partners, UK Innovation & Science Seed Fund

Description:

Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements. Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding. With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era.

Total Funding Amount:

$43.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2008-05-07

Contact Email:

info(AT)eaglegenomics.com

Founders:

Abel Ureta-Vidal, William Spooner

Number of Employees:

11-50

Last Funding Date:

2023-09-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai